ATE384265T1 - Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1) - Google Patents
Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1)Info
- Publication number
- ATE384265T1 ATE384265T1 AT01923411T AT01923411T ATE384265T1 AT E384265 T1 ATE384265 T1 AT E384265T1 AT 01923411 T AT01923411 T AT 01923411T AT 01923411 T AT01923411 T AT 01923411T AT E384265 T1 ATE384265 T1 AT E384265T1
- Authority
- AT
- Austria
- Prior art keywords
- mic
- methods
- macrophage inhibitory
- inhibitory cytokine
- diagnostic assay
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ7037A AUPQ703700A0 (en) | 2000-04-20 | 2000-04-20 | Diagnostic assay and method of treatment |
AUPQ7465A AUPQ746500A0 (en) | 2000-05-11 | 2000-05-11 | Diagnostic assay |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE384265T1 true ATE384265T1 (de) | 2008-02-15 |
Family
ID=25646308
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01923411T ATE384265T1 (de) | 2000-04-20 | 2001-04-20 | Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1) |
AT07023699T ATE470863T1 (de) | 2000-04-20 | 2001-04-20 | Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07023699T ATE470863T1 (de) | 2000-04-20 | 2001-04-20 | Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1) |
Country Status (9)
Country | Link |
---|---|
US (2) | US7514221B2 (de) |
EP (2) | EP1279039B1 (de) |
JP (1) | JP4920851B2 (de) |
AT (2) | ATE384265T1 (de) |
AU (2) | AU5018201A (de) |
CA (1) | CA2405680C (de) |
DE (2) | DE60132442T2 (de) |
ES (2) | ES2346918T3 (de) |
WO (1) | WO2001081928A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100475642B1 (ko) * | 2001-12-29 | 2005-03-10 | 한국생명공학연구원 | 암 발생 및 전이에 관여하는 단백질의 당쇄 변화를측정하여 암을 진단하는 방법 및 이를 이용한 진단킷트 |
CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CA2504508A1 (en) * | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
US7323346B2 (en) * | 2003-08-14 | 2008-01-29 | The General Hospital Corporation | Screening for gestational disorders |
KR100679666B1 (ko) * | 2004-01-20 | 2007-02-07 | 한국생명공학연구원 | 인간 대식세포 억제 사이토카인-1 특이적 단일클론항체,이를 분비하는 하이브리도마 및 이를 포함하는 위암 진단키트 |
PT2929891T (pt) | 2004-04-13 | 2020-04-08 | St Vincents Hospital Sydney Ltd | Método para modulação do apetite |
AU2005232335B2 (en) * | 2004-04-13 | 2009-09-03 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
BRPI0715126B8 (pt) | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 |
JP2010540534A (ja) * | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
US20110039284A1 (en) * | 2007-10-22 | 2011-02-17 | Samuel Norbert Breit | Methods of prognosis |
US20120107420A1 (en) | 2008-10-31 | 2012-05-03 | St Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
GB0902793D0 (en) * | 2009-02-20 | 2009-04-08 | Univ Gent | GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes |
US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
WO2011112993A2 (en) | 2010-03-11 | 2011-09-15 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pregnancy loss |
US20130203624A1 (en) * | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
EP2830646B1 (de) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen |
EP2934584B1 (de) | 2012-12-21 | 2020-02-19 | Aveo Pharmaceuticals, Inc. | Anti-gdf15-antikörper |
JP6272907B2 (ja) | 2013-01-30 | 2018-01-31 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害の処置における組成物及び使用方法 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
KR20170065026A (ko) | 2014-07-30 | 2017-06-12 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애 치료용으로 이용되는 조성물 및 방법 |
MY186702A (en) | 2014-10-31 | 2021-08-11 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
US11604194B2 (en) | 2016-02-29 | 2023-03-14 | Public University Corporation Yokohama City University | Method for detecting castration-resistant prostate cancer and detection reagent |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
WO2018187767A1 (en) * | 2017-04-06 | 2018-10-11 | The Regents Of The University Of California | Predicting, diagnosing, and treating nausea and vomiting of pregnancy |
JP7127422B2 (ja) | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
SG11202006594WA (en) * | 2018-01-15 | 2020-08-28 | Univ Nanyang Tech | Superhydrophobic platform for sensing urine metabolites and toxins |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US59431A (en) * | 1866-11-06 | Improved door-fastener | ||
WO1994003599A1 (en) * | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
US6180602B1 (en) * | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | TGF−βスーパーファミリー蛋白質をコードするヒト新規cDNA |
JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
US5994102A (en) * | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
WO1996018730A1 (en) | 1994-12-15 | 1996-06-20 | Human Genome Sciences, Inc. | Prostatic growth factor |
US6521227B1 (en) * | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
WO1997000958A1 (en) * | 1995-06-22 | 1997-01-09 | St. Vincent's Hospital Sydney Limited | NOVEL TGF-β LIKE CYTOKINE |
EP1074620A1 (de) * | 1999-08-06 | 2001-02-07 | HyGene AG | Monomer Protein der TGF-beta Familie |
AU8591198A (en) * | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
WO1999021011A1 (en) | 1997-10-23 | 1999-04-29 | Fibrogen, Inc. | Type ix collagen antibody and related uses |
US6465181B2 (en) * | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
WO2000070051A1 (en) * | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY |
-
2001
- 2001-04-20 ES ES07023699T patent/ES2346918T3/es not_active Expired - Lifetime
- 2001-04-20 AT AT01923411T patent/ATE384265T1/de active
- 2001-04-20 AT AT07023699T patent/ATE470863T1/de active
- 2001-04-20 DE DE60132442T patent/DE60132442T2/de not_active Expired - Lifetime
- 2001-04-20 EP EP01923411A patent/EP1279039B1/de not_active Expired - Lifetime
- 2001-04-20 ES ES01923411T patent/ES2300325T3/es not_active Expired - Lifetime
- 2001-04-20 WO PCT/AU2001/000456 patent/WO2001081928A1/en active IP Right Grant
- 2001-04-20 EP EP07023699A patent/EP1914554B1/de not_active Expired - Lifetime
- 2001-04-20 CA CA2405680A patent/CA2405680C/en not_active Expired - Lifetime
- 2001-04-20 AU AU5018201A patent/AU5018201A/xx active Pending
- 2001-04-20 JP JP2001578963A patent/JP4920851B2/ja not_active Expired - Lifetime
- 2001-04-20 DE DE60142372T patent/DE60142372D1/de not_active Expired - Lifetime
- 2001-04-20 AU AU2001250182A patent/AU2001250182B2/en not_active Expired
- 2001-04-20 US US10/257,597 patent/US7514221B2/en not_active Expired - Lifetime
-
2009
- 2009-02-24 US US12/379,485 patent/US7968303B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU5018201A (en) | 2001-11-07 |
CA2405680C (en) | 2018-02-13 |
AU2001250182B2 (en) | 2006-06-08 |
EP1914554A2 (de) | 2008-04-23 |
EP1279039A1 (de) | 2003-01-29 |
US20090291889A1 (en) | 2009-11-26 |
ATE470863T1 (de) | 2010-06-15 |
ES2346918T3 (es) | 2010-10-21 |
US20040053325A1 (en) | 2004-03-18 |
DE60132442D1 (de) | 2008-03-06 |
DE60132442T2 (de) | 2009-01-22 |
WO2001081928A1 (en) | 2001-11-01 |
CA2405680A1 (en) | 2001-11-01 |
EP1914554A3 (de) | 2008-08-06 |
US7968303B2 (en) | 2011-06-28 |
JP4920851B2 (ja) | 2012-04-18 |
ES2300325T3 (es) | 2008-06-16 |
DE60142372D1 (de) | 2010-07-22 |
JP2003532079A (ja) | 2003-10-28 |
EP1914554B1 (de) | 2010-06-09 |
US7514221B2 (en) | 2009-04-07 |
EP1279039A4 (de) | 2005-05-25 |
EP1279039B1 (de) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE384265T1 (de) | Diagnostischer assay mit dem makrophagen- inhibitorischen-zytokin-1 (mic-1) | |
HK1208724A1 (en) | Evaluating the efficacy of a treatment in a subject based on st2 levels st2 | |
WO2006081473A8 (en) | Methods for diagnosis and prognosis of epithelial cancers | |
WO2005010486A3 (en) | Biomarker panel for colorectal cancer | |
EP1895302A3 (de) | Verfahren zum Nachweis von kolorektalem Krebs in menschlichen Proben | |
DK1439897T3 (da) | Fremgangsmåder til adskillelse af sjældne celler fra væskeprøver | |
WO2001040517A3 (en) | Evaluating and predicting clinical outcomes by gene expression analysis | |
DE60325628D1 (de) | Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen | |
AU7494701A (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
WO2006113210A3 (en) | Diagnostic multimarker serological profiling | |
WO2003073910A3 (en) | Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples | |
HK1089511A1 (en) | Hemoglobin assay for neonatal screening | |
DE602005022709D1 (de) | Quantifizierungsverfahren für die vegf isoformen einer biologischen probe | |
WO2002102229A3 (en) | Diagnosing tumorigenicity and determining resistance to anticancer therapy | |
WO2004031414A3 (en) | Method for diagnosing prostate cancer | |
WO2004021008A3 (en) | Methods for detecting breast and ovarian cancer | |
WO2003044485A3 (en) | Proteonomic methods for diagnosis and monitoring of breast cancer | |
ATE272214T1 (de) | Verfahren zur diagnose von sepsis unter bestimmung von s100b | |
WO2002092858A3 (en) | Methods of screening for disease | |
WO2002010456A3 (en) | Multiparameter analysis for predictive medicine | |
WO2002059611A3 (en) | Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides | |
NO20034059L (no) | Fremgangsmate for screening av pre-diabetiske tilstander og screening-reagens | |
BRPI0415562A (pt) | reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma | |
PT1297342E (pt) | Metodo de diagnostico para a doenca de alzheimer com base em holo-transcobalamina ii | |
NO20042472L (no) | Lys-styrt molekylaer analyse for kreftprognose og diagnose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1279039 Country of ref document: EP |